Literature DB >> 3011152

Induction of Tac antigen and proliferation of myeloid leukemic cells by ATL-derived factor: comparison with other agents that promote differentiation of human myeloid or monocytic leukemic cells.

S Yamamoto, T Hattori, M Matsuoka, T Ishii, N Asou, M Okada, Y Tagaya, J Yodoi, K Takatsuki.   

Abstract

We studied seven cases of myeloid leukemia at various differentiation stages to investigate the response of leukemic cells to phorbol 12-myristate 13-acetate (PMA) and various biological factors. gamma-Interferon (gamma-IFN)-treated cells expressed higher amounts of Fc receptors on leukemic cells in five out of seven cases. Expression of HLA-DR antigen of gamma-IFN-treated leukemic cells was significantly enhanced in three cases. PMA did not induce Fc receptors or HLA-DR antigen on these cells. Induction of Tac antigen, a putative interleukin 2 (IL 2) receptor, was observed in two cases after cultivation with PMA or with a novel lymphokine, adult T cell leukemia-derived factor (ADF). Cells from one of these patients expressed Tac antigen immediately after cell separation, and expression of Tac antigen was augmented by PMA and ADF. Interleukin 1 (IL 1) or IL 2 did not induce Tac antigen. Leukemic cells from this patient also proliferated vigorously in the presence of ADF but not PMA, IL 1, or IL 2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011152

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  Peripheral T-cell lymphoma.

Authors:  S Watanabe; K Mukai; M Shimoyama
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

2.  Human eosinophils express functional interleukin 2 receptors.

Authors:  T H Rand; D S Silberstein; H Kornfeld; P F Weller
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

3.  Autocrine stimulation of interleukin 1 beta in acute myelogenous leukemia cells.

Authors:  K Sakai; T Hattori; M Matsuoka; N Asou; S Yamamoto; K Sagawa; K Takatsuki
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.